Stay updated on Pembrolizumab in Hypermutation Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.

Latest updates to the Pembrolizumab in Hypermutation Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.5.0 added and v3.4.3 removed.SummaryDifference0.0%

- Check8 days agoChange DetectedRevision: v3.4.3 released. The page content appears unchanged aside from the version label.SummaryDifference0.0%

- Check15 days agoChange DetectedResults have been posted for the study, including ORR, PFS, and OS outcomes with posting dates. The page now includes links to the study protocol and statistical analysis plan.SummaryDifference3%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedRevision: v3.4.2 was added to the page. The government funding lapse notice and the v3.4.1 revision information were removed.SummaryDifference0.4%

- Check44 days agoChange DetectedAdded a government funding lapse notice at the top of the page and updated the site version to v3.4.1, replacing v3.4.0; these are administrative UI changes that do not affect study details, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check51 days agoChange DetectedThe page now shows 'Results Submitted' and 'Last Update Submitted that Met QC Criteria', along with a new site revision (v3.4.0). The previous indicators like 'No Results Posted' and related status text have been removed.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab in Hypermutation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.